Skip to main content

Agios Pharmaceuticals, Inc.

corporate_fare Company Profile

Agios Pharmaceuticals, Inc.

AGIO·NASDAQ·Life Sciences·CIK 0001439222

AGIOS PHARMACEUTICALS, INC. is a commercial-stage biopharmaceutical company focused on rare disease treatment, with a foundation in hematology. The company develops and delivers innovative medicines. Its lead product candidate, mitapivat, activates both wild-type and mutant pyruvate kinase (PK) enzymes to treat hemolytic anemias. Mitapivat is approved in the United States under the brand name AQVESME™ for adults with non-transfusion dependent and transfusion-dependent alpha- or beta-thalassemia. In Saudi Arabia, it is approved under the brand name PYRUKYND® for adult patients with non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia. Mitapivat is also approved as PYRUKYND® in the United States by the FDA for treating hemolytic anemia in adults with PK deficiency, and in the European Union and Great Britain for treating PK deficiency in adults. In December 2024, the company submitted a marketing authorization application to the European Medicines Agency (EMA) and a regulatory application to the United Arab Emirates health authorities for PYRUKYND® for adult patients with non-transfusion dependent and transfusion-dependent alpha- or beta-thalassemia. In October 2025, the EMA's Committee for Medicinal Products for Human Use adopted a positive opinion for PYRUKYND® for this new indication in adults. The European Commission is reviewing this opinion, with a final decision anticipated in early 2026. The company plans a pre-supplemental New Drug Application meeting with the FDA in the first quarter of 2026.

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 20 items for AGIO at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-05, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 8 rated 8 or above. Recent SEC coverage for AGIO spans 10-Q, 8-K, 10-K.

Recent high-impact activity:

  • Agios Q3: Revenue $55.4M, Loss Narrows to $1.09/Share, $907M Cash
  • Agios Q3 Revenue Reaches $55.4M as Sickle Cell PDUFA Slips to February 2027
  • Agios Posts $1.09 Per-Share Q3 Loss as Mitapivat Decision Slips to February
  • FDA Pushes Mitapivat Sickle Cell Decision to February 2027 After Major Amendment
  • Agios Q2 Revenue Triples on AQVESME Launch; Sickle Cell PDUFA Set for Nov 1

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$54.03M
Net Income
-$412.78M
Diluted EPS
-$7.12
Op. Cash Flow
-$372.98M
Free Cash Flow
-$377.29M
Gross Profit
$47.68M
Operating Income
-$472.13M
Cash & Equivalents
$89.13M
Debt / Equity
0.00×
Net Margin
-7.64×
Shares Outstanding
58.45M sh
Source: 10-K · filed 2026-02-12 · accession 0001439222-26-000025

Short Interest & Short Volume

5.17 days to cover

FINRA reported short interest of 6,524,140 shares in AGIO as of the October 30, 2026 settlement, a 5.4% decrease from the prior period — about 5.2 days to cover at its recent average daily volume. On November 20, 2026, 43.7% of AGIO volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)6,524,140 shares as of October 30, 2026
Change vs prior period▼ 5.4%
Days to cover5.17 at avg daily volume of 1,261,811
Daily short volume (FINRA facilities)43.7% of 214,188 shares on November 20, 2026
5-day average short volume52.0%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Browse all tickers starting with A →
$27.6
52-week range · as of 2026-11-05 $22.24 – $46
Market cap
$1.65B
Volume
776.2K (0.7× avg)
3-mo avg 1.1M
Live data · 2026-11-22 05:09 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed AGIO - Latest Insights

AGIO
Nov 05, 2026, 9:38 AM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $28.75
Real-time Price: $27.60 info
Change: -$1.15 (-4%) info
Market Cap: $1.651B info
AGIO
Nov 05, 2026, 6:33 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $31.90
Real-time Price: $27.60 info
Change: -$4.30 (-13%) info
Market Cap: $1.651B info
AGIO
Nov 05, 2026, 6:30 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $31.90
Real-time Price: $27.60 info
Change: -$4.30 (-13%) info
Market Cap: $1.651B info
AGIO
Oct 30, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $37.25
Real-time Price: $27.60 info
Change: -$9.65 (-26%) info
Market Cap: $1.651B info
AGIO
Jul 30, 2026, 9:56 AM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $31.52
Real-time Price: $27.60 info
Change: -$3.92 (-12%) info
Market Cap: $1.651B info
AGIO
Jul 30, 2026, 6:32 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $36.25
Real-time Price: $27.60 info
Change: -$8.65 (-24%) info
Market Cap: $1.651B info
AGIO
Jul 30, 2026, 6:30 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $36.25
Real-time Price: $27.60 info
Change: -$8.65 (-24%) info
Market Cap: $1.651B info
AGIO
Jul 07, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $37.82
Real-time Price: $27.60 info
Change: -$10.22 (-27%) info
Market Cap: $1.651B info
AGIO
Jun 18, 2026, 4:13 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $34.16
Real-time Price: $27.60 info
Change: -$6.56 (-19%) info
Market Cap: $1.651B info
AGIO
Jun 13, 2026, 9:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $29.46
Real-time Price: $27.60 info
Change: -$1.86 (-6%) info
Market Cap: $1.651B info
AGIO
Jun 01, 2026, 5:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $29.14
Real-time Price: $27.60 info
Change: -$1.54 (-5%) info
Market Cap: $1.651B info
AGIO
May 22, 2026, 9:15 AM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $29.00
Real-time Price: $27.60 info
Change: -$1.40 (-5%) info
Market Cap: $1.651B info
AGIO
May 12, 2026, 9:30 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $27.70
Real-time Price: $27.60 info
Change: -$0.1032 (-0.37%) info
Market Cap: $1.651B info
AGIO
Apr 29, 2026, 9:22 AM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $26.47
Real-time Price: $27.60 info
Change: +$1.13 (+4%) info
Market Cap: $1.651B info
AGIO
Apr 29, 2026, 6:32 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $25.87
Real-time Price: $27.60 info
Change: +$1.73 (+7%) info
Market Cap: $1.651B info
AGIO
Apr 29, 2026, 6:30 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $24.48
Real-time Price: $27.60 info
Change: +$3.12 (+13%) info
Market Cap: $1.651B info
AGIO
Mar 02, 2026, 9:15 AM EST
Source: Reuters
Importance Score:
7
Price at Filing: $29.61
Real-time Price: $27.60 info
Change: -$2.01 (-7%) info
Market Cap: $1.651B info
AGIO
Feb 12, 2026, 9:33 AM EST
Filing Type: 10-K
Importance Score:
8
Price at Filing: $27.88
Real-time Price: $27.60 info
Change: -$0.280 (-1%) info
Market Cap: $1.651B info
AGIO
Feb 12, 2026, 6:32 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $28.55
Real-time Price: $27.60 info
Change: -$0.950 (-3%) info
Market Cap: $1.651B info
AGIO
Jan 12, 2026, 7:11 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $28.50
Real-time Price: $27.60 info
Change: -$0.900 (-3%) info
Market Cap: $1.651B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets